News
Neurostatus-EDSS for Pathway: Improved MS outcome assessment capabilities are now available on the VeraSci eCOA Platform
VeraSci, a leading provider of innovative scientific and technology services, announced today the expansion of their proprietary eCOA platform to fully integrate the Neurostatus-EDSS assessment and Neurostatus data clarification services for MS trials. VeraSci...
Examination of Inconsistent MDS-UPDRS Ratings in the Parkinson’s Progression Marker Initiative
“Inconsistent Movement Disorders Society-Unified Parkinson’s Disease Rating Scale Part III Ratings in the Parkinson’s Progression Marker Initiative” co-authored by VeraSci expert Dr. Travis Turner was recently published in Movement Disorders. The Parkinson’s Progression Markers Initiative (PPMI) study looked at the ratings of Part III of the Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) performed by site investigators trained by online training. The study identified likely errors resulting from transcription and data entry and suggests that employing a direct data capture method like eCOA could result in higher quality data.
Dr. Luca Pani Co-authors Article on the Implications of Reimbursement Limits on Patient Access
The European Review for Medical and Pharmacological Sciences recently published “Impact of reimbursement limits on patient access to direct-acting antivirals in Italy: analysis of data from national registries” co-authored by Dr. Luca Pani, VP Regulatory Strategy and Market Access Innovation at VeraSci. The study looked at patients in Italy with Hepatitis C treated with Direct Antiviral Agents (DAA) when Dr. Pani was the Director General of the Italian Medicines Agency (2011-2016) and after that (2017-2018).
Understanding the Impact of Widespread Testing in Controlling the Spread of COVID-19 and on Europe’s Economy
Vital Transformation, a consultancy focused on addressing the challenges of modern healthcare systems, recently reviewed country-level COVID-19 data to determine the impact of widespread testing on both the spread of COVID-19 and the economic impact of...
Analyses of Pharmaceutical Industry Data Shows Increase in R&D Productivity
Last week, the Journal of Translational Medicine published a report on the increase in R&D productivity in the industry. The article published the results of analyses of pharmaceutical industry data for the past decade. Dr. Luca Pani, VP Regulatory...
Update on VeraSci’s Business Operations During the COVID-19 Pandemic
VeraSci is taking all appropriate measures to ensure business continuity and employee health and safety. The governments of the United States and the state of North Carolina have declared a state of emergency, and NC has issued a stay-at-home order effective through...
Innovative Trial Results Published in Nature Medicine
This week, Nature Medicine published results from an innovative trial in anhedonia. Anhedonia, or lack of pleasure, is a key symptom in a number of mood and anxiety disorders including depression. VeraSci experts Dr. Rich Keefe, CEO, and Trina Walker, VP Clinical...
Update on VeraSci’s Response to COVID-19
VeraSci is taking all appropriate measures to ensure our staff are prepared to continue business operations over the next several weeks. The governments of the United States and our state of North Carolina have declared a state of emergency and have encouraged...
VeraSci’s Response to COVID-19
We wanted to inform you on VeraSci’s current response and policy formation regarding COVID-19, the coronavirus. VeraSci’s office is currently open. We are taking all appropriate measures to ensure our staff are prepared to continue business operations over the next...
Dr. Rich Keefe Co-authors Article on a Novel Digital Intervention for ADHD in The Lancet Digital Health
The Lancet Digital Health published the article “A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD); a randomized controlled trial” on Monday, February 24. VeraSci CEO Dr. Rich Keefe was a co-author on this article. The article...